Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessing Optimal XR-Buprenorphine Initiation Points in Jail
NCT05481112Phase 4Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Proportion of Participants who Receive XR-B within 28 Days Prior to Jail Release. Planned start Nov 2023; status: withdrawn.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05481112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481112.